Dyadic International Secures $2.9 Million in Registered Direct Offering to Boost Protein Production Platforms

Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase an equal number of shares. The offering is priced at $0.795 per common share and $0.005 per warrant, with warrants exercisable at $0.84 per share. The transactions are expected to generate aggregate gross proceeds of approximately $2.9 million, with closing anticipated on or about Aug. 14, 2026, subject to customary conditions.

This capital infusion is poised to bolster Dyadic's mission to develop and commercialize scalable, non-animal protein production platforms. These platforms address the growing global demand in life sciences, food and nutrition, and bio-industrial markets. By enabling the production of high-value proteins efficiently and sustainably, Dyadic's proprietary Dapibus™ and C1 expression systems offer rapid, cost-effective manufacturing solutions. The net proceeds from this offering, combined with existing cash reserves and investment-grade securities, will be allocated to working capital and general corporate purposes, ensuring the company can advance its innovative technologies.

The significance of this funding extends beyond Dyadic's balance sheet. For Texas, a state with a robust biotechnology and food innovation sector, Dyadic's advancements could catalyze local economic growth by attracting partnerships and creating high-skilled jobs. The company's focus on non-animal proteins aligns with global sustainability trends, potentially reducing environmental impact and meeting consumer demand for ethical and eco-friendly products. Moreover, the efficiency of Dyadic's expression systems could lower production costs for biologics, making life-saving therapies more accessible.

Aegis Capital Corp. is serving as the exclusive placement agent for the offerings, a move that underscores investor confidence in Dyadic's strategic direction. The company's ability to secure institutional investment reflects the market's recognition of its potential to disrupt traditional protein production methods. As industries worldwide seek alternatives to animal-derived components, Dyadic's technology positions it as a key player in the transition toward sustainable biomanufacturing.

For stakeholders in Texas and beyond, this development signals a step forward in the commercialization of innovative biotech solutions. The funds will enable Dyadic to scale its operations, potentially accelerating the timeline for bringing new products to market. This could have far-reaching implications for sectors ranging from pharmaceuticals to alternative proteins, fostering a more resilient and sustainable supply chain. As Dyadic advances its platforms, the impact on the industry may be profound, offering a blueprint for how biotechnology can address global challenges while driving economic progress.